The achievement of the sale is not the end of the story. It is true to say that without sales nothing happens, but many different factors must be used to judge the absolute value of a sale. The sales executive may appear to be very efficient, but unless a meaningful relationship has been created between the buyer and the seller, the overall or net value of the transaction can be questioned. In this analysis, incentives must be prepared and deployed selectively, with the aim of achieving a “win-win” solution all around.

Productivity generally increases if an individual is incentivised, as this is within our nature. This will require the creation of sensible goals related to existing benchmarks. Correct incentivisation will enhance the effectiveness of the sales force, but the opposite is also true. The goals set should represent a journey rather than the destination and multi-tiered targets should encourage, but always lead to a “carrot” which is just out of reach. In this way, the sales executive will be always focused.

Feedback from pharmaceutical consulting firms will tell us that sales executives are often engaged with mundane and administrative work and spend only a small amount of their time directly communicating with productive targets. This is why time management should be considered as a top priority and company executives should never put onerous administrative and accounting burdens in front of their productive sales team. Indeed, if these boring tasks get completely out of control, certain personality types can rebel and this can have a serious, knock-on effect on creativity and achievements.

If a comprehensive training program is practised by the organisation, each team member will get the feeling that he or she is dynamically engaged with the overall goal. Do not confuse administration with training – training is a priority, while administrative burdens should be minimised. This should include product awareness as well as methodology and techniques, and the latest procedures can be implemented through pharma consulting firms. Such companies have been proven to raise morale, cut out negative emotions, inject just the right amount of enthusiasm and draw on their extensive industry background.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

Senior management must ensure that all members are team players. From an overall perspective, effective marketing requires good management of this team and this is where pharmaceutical consultants are worth their weight in gold. The team members must be able to quantify and visualise and objectives must be controlled and measured at all times. The daily initiatives must be seen as part of an overall and tangible goal and the team should be able to work as a cohesive unit for best results to be achieved.

After planning is complete, the sales force must put it into action. Although you cannot underestimate the importance of planning and preparation, sales executives must now venture into the real world. While a sales team may be composed of experienced players, there is nevertheless a lot to learn about the health care industry in particular and training is an essential part of staff handling. Without adequate coaching and being unaware of potential loopholes ahead, time can be wasted and worse still, clients can be overlooked or lost in such a competitive marketplace. As they have a considerable amount of experience in the industry, pharma consulting firms appreciate time management and know that full application and dedication is required before key results may be achieved.

It is never good to assume anything, as this could lead to confusion and delay. To be effective, the sales team member must be fully aware of the cohesive importance of a true team. Each member has a significant contribution to make and these contributions should be visible and not opaque. Once again, the overall goal is to engage and not to procrastinate. Three critical components make up an effective salesperson – creativity, assertiveness and flair.

Out in the market, a salesperson must be completely educated in all the benefits, solutions, finer details and product availability, while also being able to think quickly, reschedule and meet goals. Certain key skills must be in evidence before success may be achieved, but this can certainly be enhanced by full training, great management and team cohesiveness. Generally, pharmaceutical consulting organisations are by far best positioned to take on these critical challenges.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

Pharmaceutical companies must conform to strict FDA regulations, best use practices and study scientific benchmarks to provide products and services for ongoing use. The importance of marketing in this environment should never be underestimated. The physician or pharmacist has to juggle a lot of information, much of it based on older science, together with the wants and needs of the patient and budgetary restrictions applied by insurance companies or individual positions.

The direct communication between health care professionals and the pharmaceutical companies through various marketing channels ultimately dictates the efficient delivery of products and services to the end-user, the patient. There is a lot at stake as the patient's ability to lead a healthy and productive life can be affected by the quality and standard of the marketing trail. It’s crucial to remember that these forms of marketing represent a two way street. In addition to the company's communication with the professional about the benefits and risks associated, the science behind the introduction of the products and ways for dissemination and consumption, the professional also communicates back to the company with feedback, real-time findings and data.

The fact that pharma consulting can provide cutting-edge information about conditions and treatments, spotlighting certain illnesses which may not have received much attention, should not be underestimated. We still have many conditions without a cure and pharmaceutical company research can often go a long way to bridging that gap, if not even enabling cutting-edge treatment for patients. There is no guarantee that such amazing products may even find their way into the hands of the sufferer. As such, marketing is pivotal in helping to relay this information from the manufacture, through the professional to the end-user.

As more and more information is revealed through scientific study, product creation and government rubber-stamping, more of a spotlight is turned on the need for treatment of chronic diseases. For example, certain side effects or by-products of a critical element may not have been apparent, or the link between illness and cure revealed, unless and until adequate marketing channels are open between the researchers, producers, professionals and patients.

Generally, pharmaceutical consulting firms are highly skilled at developing communication between vital parties and educating all players. Their experience, knowledge and enthusiasm can really help to turn the wheels of the marketing machine, continuously engaging all key players and producing incredible results in such a competitive environment.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.

A pharmaceutical company is far more than just a manufacturer of health products and solutions. The pharmaceutical consulting firm helps the company understand how it needs to educate the consumer. Pharmaceutical companies regularly operate on the sharp end of discovery and their revelations may be truly ground-breaking. If they have not paid sufficient attention to marketing, all the exploratory work may fail as the path through the regulators to the professionals may seem unclear. Marketing also insists that the product features and benefits are correctly communicated to the financiers, principally the insurance companies, who seem to have an ever-increasing role in the dissemination of care.

While regulators will ultimately determine if a pharmaceutical product may be made available and will confirm the associated claims, the pharmaceutical company must be able to market itself, its reputation and its products within the ultra-competitive and distracted healthcare industry. There are a lot of vested interests to take into account and some of these interests may promote older or generic medications, sometimes to the general detriment of the patient. Pharmaceutical companies must create a position within such a difficult marketplace, in order to push science and discovery and their own significant position forward.

It is unfortunate that the ultimate care of the patient is very often not the ultimate goal of certain vested interests. In popular opinion, healthcare reform is always controversial and the pharmaceutical company would do well to accurately and forcefully communicate its position. The physician takes input from many different sources before he or she makes the decision as to final care, including experience, peer input, education and training, patient history, formularies, techniques and benchmarks - all play their role. If you consider that nine out of ten most frequently prescribed drugs are generics, it should be clear that far from being in a position of dominance, pharmaceutical companies must make every effort to ensure that their marketing messages are heard. In most cases, pharma consulting firms are used to this difficult environment and can certainly help to open channels and engage practices.

Many of the most striking advances in the dissemination of medicine in recent years have been a result of work by pharmaceutical companies. Previous generations would surely marvel at some of the cures available today. Much emphasis must be put on marketing “the word” to ensure that our health care continues to improve.

Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.

Far too often the act of a sale is construed as a perfect result. While winning a sale is undoubtedly important, as after all without sales nothing is achieved, there must be tangible and measurable value attached to the sale, from every point of view. The sales executive may appear to be very efficient, but unless a meaningful relationship has been created between the buyer and the seller, the overall or net value of the transaction can be questioned. In this analysis, incentives must be prepared and deployed selectively, with the aim of achieving a “win-win” solution all around.

It is human nature for an individual to likely be more productive if he or she is incentivised. This will require the creation of sensible goals related to existing benchmarks. If this is handled correctly it will create a volatile and effective environment, but it can also be detrimental if handled poorly. The goals set should represent a journey rather than the destination and multi-tiered targets should encourage, but always lead to a “carrot” which is just out of reach. This will ensure that the sales executive is constantly engaged.

Feedback from pharmaceutical consulting firms will tell us that sales executives are often engaged with mundane and administrative work and spend only a small amount of their time directly communicating with productive targets. Due to this amazing statistic, time management should be a top priority and executives should do whatever they can to cut down on the ancillary or administrative work necessary. Creativity and enthusiasm can be stifled within certain outgoing personality types, through the imposition of onerous or even boring demands.

If a comprehensive training program is practised by the organisation, each team member will get the feeling that he or she is dynamically engaged with the overall goal. While administrative burdens should be kept to a minimum as we have said, training must nevertheless be prioritised. This should include product awareness as well as methodology and techniques, and the latest procedures can be implemented through pharma consulting firms. Such companies have been proven to raise morale, cut out negative emotions, inject just the right amount of enthusiasm and draw on their extensive industry background.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

The achievement of the sale is not the end of the story. While winning a sale is undoubtedly important, as after all without sales nothing is achieved, there must be tangible and measurable value attached to the sale, from every point of view. The sales executive may appear to be very efficient, but unless a meaningful relationship has been created between the buyer and the seller, the overall or net value of the transaction can be questioned. In this analysis, incentives must be prepared and deployed selectively, with the aim of achieving a “win-win” solution all around.

Productivity generally increases if an individual is incentivised, as this is within our nature. Create sensible goals to move the sales force forward. If this is handled correctly it will create a volatile and effective environment, but it can also be detrimental if handled poorly. Rather than setting a goal, the incentive path should be a journey with multiple tiers and an endpoint that is always just out of reach. This will ensure that the sales executive is constantly engaged.

Feedback from pharmaceutical consulting firms will tell us that sales executives are often engaged with mundane and administrative work and spend only a small amount of their time directly communicating with productive targets. This is why time management should be considered as a top priority and company executives should never put onerous administrative and accounting burdens in front of their productive sales team. Indeed, if these boring tasks get completely out of control, certain personality types can rebel and this can have a serious, knock-on effect on creativity and achievements.

A sales force will only be really effective if a comprehensive training process is in place and the team member must feel that he or she is part of a dynamic organisation. While administrative burdens should be kept to a minimum as we have said, training must nevertheless be prioritised. Generally, pharma consulting firms can help to roll out the latest in procedures, educate in technical issues and methodology and focus on product awareness. These companies can bring a lot to the corporate table, using an extensive industry background, a variety of different perspectives, pep talks and rallies at just the right time to eliminate even the traces of negative emotions.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

A pharmaceutical company faces many challenges, quite apart from the manufacture of its products. The pharmaceutical consulting firm helps the company understand how it needs to educate the consumer. Pharmaceutical companies regularly operate on the sharp end of discovery and their revelations may be truly ground-breaking. If they have not paid sufficient attention to marketing, all the exploratory work may fail as the path through the regulators to the professionals may seem unclear. Marketing also insists that the product features and benefits are correctly communicated to the financiers, principally the insurance companies, who seem to have an ever-increasing role in the dissemination of care.

Before a new product may arrive on the desk of the regulators, who determine its future, the company must have marketed both its products and its history within a very competitive and busy environment. There are a lot of vested interests to take into account and some of these interests may promote older or generic medications, sometimes to the general detriment of the patient. Pharmaceutical companies must create a position within such a difficult marketplace, in order to push science and discovery and their own significant position forward.

Sometimes, the vested interests are very powerful and do not serve the ultimate client best. In popular opinion, healthcare reform is always controversial and the pharmaceutical company would do well to accurately and forcefully communicate its position. The physician takes input from many different sources before he or she makes the decision as to final care, including experience, peer input, education and training, patient history, formularies, techniques and benchmarks - all play their role. Statistics tell us that 90% of the most frequently prescribed drugs are generics and thus it is difficult for pharmaceutical companies to ensure that they are being heard in the right place at the right time. Generally, pharma consulting firms play their part in helping to establish channels and best practices.

Many of the most striking advances in the dissemination of medicine in recent years have been a result of work by pharmaceutical companies. Previous generations would surely marvel at some of the cures available today. To enable healthcare to continue to get better, much emphasis must be placed on marketing.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

A pharmaceutical company has many different stakeholders and must satisfy a number of different “clients.” The company is always involved in industry positioning, political lobbying, public relations and media, as well as the fundamental issues of sales, marketing and financial measurements. There is so much on the plate, be it daily or weekly and there is always a danger that senior management may take on too many issues and end up being less effective overall. Key account management will not be effective if certain layers of communication are not maintained, leading to a less efficient sales and marketing operation and calling for a pharmaceutical consulting firm to be retained for best effect.

Following the appointment of a specific account to the role of “key,” the pharmaceutical consultants should help in composing a concerted plan of action. The business must look at the relationship from the client point of view and accurately gauge what they feel to be the substance of the relationship. There should be an interactive approach to communication here and the goal should be to create a “win-win” scenario at all times, regardless of complexity. While attention to the essentials is of course important, the key account would be more likely to continue the association if additional value is perceived.

A comfort zone must be the desired result, for if the client senses this, then a continuation can be expected and an expansion possible. Trust is everything and the establishment of a comfort zone promotes the client to relax many of the resources it may engage to control the associated activities, marking the relationship as efficient in its eyes.

It has been said that account management is often one of “damage control.” Certainly issues and problems will arise from time to time. It falls to the company to try and understand how a client works and to do its best to anticipate any problems or objections before they occur. The more educated the sales and marketing team and the better the training levels initiated, the more likely it is that any potential stumbling blocks will be easily resolved.

Key account management requires a constant review of the client's interpretation of the relationship. As always, a level of satisfaction is at the top of the list and when senior management goes overboard, a long-term relationship is likely, with great potential for additional revenues. In almost every instance, pharma consulting firms practice the art of delivering satisfaction.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

Pharmaceutical companies must conform to strict FDA regulations, best use practices and study scientific benchmarks to provide products and services for ongoing use. Marketing plays a critical role in this arrangement and is far more than just a means to an end. The physician or pharmacist has to juggle a lot of information, much of it based on older science, together with the wants and needs of the patient and budgetary restrictions applied by insurance companies or individual positions.

The direct communication between health care professionals and the pharmaceutical companies through various marketing channels ultimately dictates the efficient delivery of products and services to the end-user, the patient. It follows that the standard of this marketing and its effectiveness directly contributes to the patient's ability to live a longer, healthier and more productive life. It’s crucial to remember that these forms of marketing represent a two way street. In addition to the company's communication with the professional about the benefits and risks associated, the science behind the introduction of the products and ways for dissemination and consumption, the professional also communicates back to the company with feedback, real-time findings and data.

The contribution of pharma consulting should never be underestimated as it can help to emphasise how certain conditions can be treated by emerging products and help to reveal how other illnesses, previously under-served, could be addressed. Where treatment gaps may have previously existed, the research and work done by the pharmaceutical companies can also raise awareness and enable treatment for patients who may not have realised the treatment was available. Just because the pharmaceutical products may exist, it does not mean that these products will find their way into the hands of the consumer. Marketing plays a critical role in disseminating the information from one end of the chain to the other, into the hands of the professionals for communication with the patient.

As more and more information is revealed through scientific study, product creation and government rubber-stamping, more of a spotlight is turned on the need for treatment of chronic diseases. As such, any by-products or side effects of new solutions may not become known, nor the link between cure and original illness exposed, unless strong marketing channels are open between all concerned.

Generally, pharmaceutical consulting firms are highly skilled at developing communication between vital parties and educating all players. Their interaction, encouragement and foresight can help to ensure that the marketing machine is primed and key players are aware of each other's vital contributions, so important in this hyper-competitive environment.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.